Literature DB >> 15025718

A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length.

D R Langbehn1, R R Brinkman, D Falush, J S Paulsen, M R Hayden.   

Abstract

Huntington's disease (HD) is a neurodegenerative disorder caused by an unstable CAG repeat. For patients at risk, participating in predictive testing and learning of having CAG expansion, a major unanswered question shifts from "Will I get HD?" to "When will it manifest?" Using the largest cohort of HD patients analyzed to date (2913 individuals from 40 centers worldwide), we developed a parametric survival model based on CAG repeat length to predict the probability of neurological disease onset (based on motor neurological symptoms rather than psychiatric onset) at different ages for individual patients. We provide estimated probabilities of onset associated with CAG repeats between 36 and 56 for individuals of any age with narrow confidence intervals. For example, our model predicts a 91% chance that a 40-year-old individual with 42 repeats will have onset by the age of 65, with a 95% confidence interval from 90 to 93%. This model also defines the variability in HD onset that is not attributable to CAG length and provides information concerning CAG-related penetrance rates.

Entities:  

Mesh:

Year:  2004        PMID: 15025718     DOI: 10.1111/j.1399-0004.2004.00241.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  302 in total

1.  Basal ganglia atrophy in prodromal Huntington's disease is detectable over one year using automated segmentation.

Authors:  D S Adnan Majid; Adam R Aron; Wesley Thompson; Sarah Sheldon; Samar Hamza; Diederick Stoffers; Dominic Holland; Jody Goldstein; Jody Corey-Bloom; Anders M Dale
Journal:  Mov Disord       Date:  2011-09-19       Impact factor: 10.338

Review 2.  Huntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics.

Authors:  Tiago A Mestre; Cristina Sampaio
Journal:  Curr Neurol Neurosci Rep       Date:  2017-02       Impact factor: 5.081

3.  Stability of resting fMRI interregional correlations analyzed in subject-native space: a one-year longitudinal study in healthy adults and premanifest Huntington's disease.

Authors:  Tyler M Seibert; D S Adnan Majid; Adam R Aron; Jody Corey-Bloom; James B Brewer
Journal:  Neuroimage       Date:  2011-09-10       Impact factor: 6.556

4.  "Frontal" behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness.

Authors:  Kevin Duff; Jane S Paulsen; Leigh J Beglinger; Douglas R Langbehn; Chiachi Wang; Julie C Stout; Christopher A Ross; Elizabeth Aylward; Noelle E Carlozzi; Sarah Queller
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2010       Impact factor: 2.198

5.  Key role of nuclear medicine in seeking biomarkers of Huntington's disease.

Authors:  Ferdinando Squitieri; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06       Impact factor: 9.236

6.  Huntington's disease: changes in saccades and hand-tapping over 3 years.

Authors:  Chrystalina A Antoniades; Zheyu Xu; Sarah L Mason; R H S Carpenter; Roger A Barker
Journal:  J Neurol       Date:  2010-06-29       Impact factor: 4.849

7.  Challenges assessing clinical endpoints in early Huntington disease.

Authors:  Jane S Paulsen; Chiachi Wang; Kevin Duff; Roger Barker; Martha Nance; Leigh Beglinger; David Moser; Janet K Williams; Sheila Simpson; Douglas Langbehn; Daniel P van Kammen
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

8.  Brain metabolite alterations and cognitive dysfunction in early Huntington's disease.

Authors:  Paul G Unschuld; Richard A E Edden; Aaron Carass; Xinyang Liu; Megan Shanahan; Xin Wang; Kenichi Oishi; Jason Brandt; Susan S Bassett; Graham W Redgrave; Russell L Margolis; Peter C M van Zijl; Peter B Barker; Christopher A Ross
Journal:  Mov Disord       Date:  2012-05-30       Impact factor: 10.338

9.  ROBUST MIXED EFFECTS MODEL FOR CLUSTERED FAILURE TIME DATA: APPLICATION TO HUNTINGTON'S DISEASE EVENT MEASURES.

Authors:  Tanya P Garcia; Yanyuan Ma; Karen Marder; Yuanjia Wang
Journal:  Ann Appl Stat       Date:  2017-07-20       Impact factor: 2.083

10.  Abnormal brain development in child and adolescent carriers of mutant huntingtin.

Authors:  Ellen van der Plas; Douglas R Langbehn; Amy L Conrad; Timothy R Koscik; Alexander Tereshchenko; Eric A Epping; Vincent A Magnotta; Peggy C Nopoulos
Journal:  Neurology       Date:  2019-08-01       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.